ReviewCureus2025
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the significant comorbidities in patients with inflammatory bowel disease (IBD). This systematic review and meta-analysis aimed to synthesize existing evidence on NAFLD prevalence in IBD patients and explore sources of heterogeneity. A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, Web of Science, and Scopus from January 2016 to September 2025, including studies reporting NAFLD prevalence in adult IBD patients diagnosed through imaging, biopsy, or validated biomarkers. Two independent reviewers screened studies and extracted data on patient demographics, IBD subtypes, and NAFLD diagnostic methods. Quality assessment was performed using the Newcastle-Ottawa Scale. Thirty-five studies encompassing over 47 million IBD patients were included. The pooled prevalence of NAFLD in IBD patients was 26% (95% CI: 23-29%), with substantial heterogeneity (I² = 99.9%). Subgroup analysis revealed a higher prevalence in cross-sectional studies (40.9%) compared to retrospective studies (19.5%). Crohn's disease patients demonstrated higher NAFLD prevalence (26.1%) than ulcerative colitis patients (17.0%). Studies published from 2020 onwards reported a slightly higher prevalence (27.5%) compared to earlier studies (24.8%). The findings indicate that approximately one in four IBD patients has concurrent NAFLD, representing a substantial comorbidity burden. These results underscore the importance of systematic NAFLD screening in IBD patients and integrated multidisciplinary care addressing both gastrointestinal and metabolic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.